India, July 31 -- Moleculin Biotech, Inc. (MBRX) on Friday announced the pricing of a public offering expected to generate gross proceeds of about $9.3 million.
The offering comprises of 12.38 million common shares, or pre-funded warrants in lieu thereof, along with accompanying common warrants to purchase up to 37.13 million shares of common stock, at a combined public offering price of $0.75 per share, or pre-funded warrant in lieu thereof, and associated warrants.
The accompanying common warrants will be immediately exercisable at an exercise price of $0.75 per share and will expire five years from the initial exercise date.
The offering is expected to close on or about August 3, 2026, subject to customary closing conditions.
googlet...